Patent intelligence · WO
WO 2020012244
TRAITEMENT DE LA RECTOCOLITE HÉMORRAGIQUE AU MOYEN DE BRAZIKUMAB
TRAITEMENT DE LA RECTOCOLITE HÉMORRAGIQUE AU MOYEN DE BRAZIKUMAB
Patent details — WO 2020012244
- Jurisdiction
- WO
- Status
- granted
- Grant date
- Jan 16, 2020
- Expiration
- Jan 11, 2040
- Applicant
- ALLERGAN PHARMACEUTICALS INT LTD [IE]
- CPC classes
- A61K 39/ 02 A I, A61K 39/ 39 A I, A61K/3902, A61K/3939
Quick answer
WO 2020012244 (TRAITEMENT DE LA RECTOCOLITE HÉMORRAGIQUE AU MOYEN DE BRAZIKUMAB) is held by ALLERGAN PHARMACEUTICALS INT LTD [IE]. Status: granted. Granted Jan 16, 2020. Expires Jan 11, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ALLERGAN PHARMACEUTICALS INT LTD [IE]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 39/ 02 A I, A61K 39/ 39 A I, A61K/3902, A61K/3939, A61K/90019, A61P/100
More from ALLERGAN PHARMACEUTICALS INT LTD [IE]
Related pharmaceutical patents in our USPTO index.
-
US 12383545
TREATMENT OF MIGRAINE
granted -
US 2025064788
TREATMENT OF MIGRAINE
granted -
US 2024180883
TREATMENT OF MIGRAINE
granted -
WO 2024081718
ANTAGONISTE DU RÉCEPTEUR CGRP POUR LE TRAITEMENT DE LA MIGRAINE
granted -
CA 3244873
TRAITEMENT PRÉVENTIF DE LA MIGRAINE
granted -
WO 2023077094
TRAITEMENT D'UN TROUBLE DÉPRESSIF MAJEUR
granted -
US 2023130736
METHODS OF TREATING MIGRAINE
granted -
US 2022380379
PHARMACEUTICAL COMPOUNDS
granted
Frequently asked questions
What is US patent 2020012244?
WO 2020012244 (TRAITEMENT DE LA RECTOCOLITE HÉMORRAGIQUE AU MOYEN DE BRAZIKUMAB) is held by ALLERGAN PHARMACEUTICALS INT LTD [IE]. Status: granted. Granted Jan 16, 2020. Expires Jan 11, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Who owns WO 2020012244?
ALLERGAN PHARMACEUTICALS INT LTD [IE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does WO 2020012244 expire?
Our index shows an expiration date of Jan 11, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.